Publications
(View metrics and citation profile on Google Scholar)

Skorodumov I, Walter F, Akan M, Buchborn T, et al. (2026). Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC. doi.org/10.21203/rs.3.rs-9103509/v1 (open access). 

Andrade FRT, Buchborn T, Thalheimer G, Meinhardt M, Joca S, Martins de Almeida RM (2025). Exploring the Effects of Psilocybin on Depression and the Mediating Role of the 5-HT2A Receptor: A Systematic Review. Acta Neuropsychiatr. 37, e86, 1–22. doi.org/10.1017/neu.2025.10039 (open access).

Song C, Chang T, Buchborn T, Knöpfel T (2025). Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition. Biorxiv, doi.org/10.1101/2025.03.10.642385 (open access).

Heller N, Barrett F, Buchborn T, Collerton D, Dupuis D, Halberstadt A, Jardri R, Noorani T, Preller K, Taylor JP, Waters F, Winston B, and Leptourgos P (2025). Visual Hallucinations in Serotonergic Psychedelics and Lewy Body diseases. Schizophr. Bull., Vol. 51, Issue Suppl. 3, S273–S291. doi.org/10.1093/schbul/sbaf068 (open access).

Buchborn T, Kettner H, Kaertner L, Meinhardt M (2023). The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression. Front. Neurosci., 17. doi.org/10.3389/fnins.2023.1232459 (open access).

Buchborn T, Lyons T, Song C, Feilding A, Knöpfel T (2023). Cortical Correlates of Psychedelic-Induced Shaking Behavior Revealed by Voltage Imaging. Int. J. Mol. Sci., 24, 9463. doi.org/10.3390/ijms24119463 (open access).

Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL (2023). Body mass index (BMI) does not predict responses to psilocybin. J. Psychopharmacol., 37, 1, 107-116. doi.org/10.1177/02698811221131994 (open access).

Kärtner L, Steinborn M, Kettner H, Spriggs M, Roseman L, Buchborn T, Balaet M, Timmermann C, Erritzoe D, Carhart-Harris R (2021). Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci. rep., 11, 1941. doi.org/10.1038/s41598-021-81446-7 (open access).

Buchborn T (2020). Verhaltens- und molekularbiologische Untersuchungen zur Grundlage der Toleranz gegenüber serotonergen Halluzinogenen. Dissertation. Otto-von-Guericke Univ., Magdeburg. doi.org/10.25673/35375 (open access).

Buchborn T, Lyons T, Song C, Feilding A, Knöpfel T (2020). The 5-HT2AR agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner. J. Psychopharmacol., 34, 7, 786–794. doi: 10.1177/0269881120903465 (open access).

Buchborn T, Lyons T, Knöpfel T (2018). Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice. Front. pharmacol., 9, 17. doi: 10.3389/fphar.2018.00017 (open access).

Buchborn T, Grecksch G, Dieterich DC, Höllt V (2016). Tolerance to lysergic acid diethylamide (LSD): Overview, correlates, and clinical implications. In: Preedy VR (ed.), Neuropathology of Drug Addictions and Substance Misuse, Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects, 846-858. Academic Press. doi:10.1016/B978-0-12-800212-4.00079-0 (green open access).

Buchborn T, Schröder H, Koch T, Kahl E, Dieterich DC, Grecksch G, Höllt V (2016). Differential tolerance to lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT) – A matter of serotonin (5-HT) 2A receptor downregulation? Naunyn-Schmiedeberg's Arch. Pharmacol., 389, Suppl. 1, S63.

Buchborn T, Schröder H, Dieterich DC, Grecksch G, Höllt V (2015). Tolerance to LSD and DOB induced Shaking behaviour: Differential adaptations of frontocortical 5-HT2A and glutamate receptor binding sites. Behav. Brain Res., 281, 62–68. doi:10.1016/j.bbr.2014.12.014 (green open access).

Buchborn T, Schröder H, Höllt V, Grecksch G (2014). Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling.  J. Psychopharmacol., 28, 6, 545-552. doi: 10.1177/0269881114531666 (green open access).

Buchborn T, Kahl E, Höllt V, Koch T (2012). Agonist-selective internalization of the human 5-HT2A receptor. Naunyn-Schmiedeberg´s Arch. Pharmacol., 385, Suppl. 1, S17. doi: 10.1007/s00210-012-0736-0 (open access).